Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

CJC-1295

CJC-1295 with DAC, CJC-1295 no DAC

Category 1
Growth Hormone Secretagogue

Sermorelin

Geref, GRF 1-29

Category 1
Growth Hormone Secretagogue
Overview

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone. Available with or without a Drug Affinity Complex (DAC) that extends its half-life.

A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). One of the longest-studied GH-releasing peptides with a history of FDA approval for pediatric GH deficiency.

Mechanism of Action

Binds to GHRH receptors on the pituitary gland, stimulating pulsatile release of growth hormone. The DAC version binds to albumin in the blood, extending the half-life from minutes to approximately 6-8 days.

Directly stimulates the pituitary gland to produce and release growth hormone through the natural GHRH pathway. Maintains the body's natural feedback mechanisms, reducing the risk of GH excess.

Common Uses
  • Growth hormone optimization
  • Improved sleep quality
  • Fat loss
  • Muscle recovery
  • Anti-aging protocols
  • Growth hormone deficiency treatment
  • Anti-aging protocols
  • Improved sleep
  • Body composition improvement
  • Recovery enhancement
Known Risks
  • Water retention
  • Tingling or numbness
  • Potential cortisol elevation
  • Limited long-term safety data
  • May affect blood sugar levels
  • Injection site reactions (redness, swelling)
  • Headaches
  • Flushing
  • Dizziness
  • Generally well-tolerated in clinical studies
Regulatory Status
Category 1

Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.

Category 1

Previously FDA-approved as Geref for diagnostic use and pediatric GH deficiency (withdrawn from market for commercial reasons, not safety). Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.